The BIO convention may be hosted by Boston this year, but that hasn’t stopped other states from getting in on the action.

Biogen has offered to buy all the shares in Sage Therapeutics that it doesn't already own, taking control of their novel antidepressant Zurzuvae. The $7.22-per-share deal for 89.8% of Sage is a 30 ...

5:53 AM ESTHealth Care Sage rejects Biogen’s buyout offer, but says it's open to deals Sage rejects Biogen’s buyout offer, but says it's open to deals ...

Biogen has decided to close down its digital health unit, formed just two years ago, as part of a major cost-reduction drive that has already claimed thousands of jobs. The decision – first ...

The revolution that’s been happening in financial services is right in your pocket: the phone that you pull out when the check arrives after a restaurant dinner with friends. Until relatively recently ...

With Viatris taking home the biggest prize at this year’s Cannes Pharma Lions award and Biogen winning Gold, pharma is making a comeback. After a lackluster showing in 2024 extended a yearslong ...

Oral anticoagulants (OACs) are medications commonly used in patients with atrial fibrillation and other cardiovascular conditions. Both warfarin and direct oral anticoagulants are susceptible to ...

Much has transpired since the last scientific statement on pediatric stroke was published 10 years ago. Although stroke has long been recognized as an adult health problem causing substantial ...

This data feed is not available at this time. Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.